Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN3B | O60391 | 12/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 12/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL29365874 | 1.00 | GRIN3B (0.36) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL29998454 | 0.84 | DAO (0.46) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL198179 | 0.84 | GRIN3B (0.38) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL199636 | 0.84 | DAO (0.46) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL10288661 | 0.83 | USP7 (0.42) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL2210877 | 0.83 | SIRT3 (0.46) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL198645 | 0.83 | DAO (0.44) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| Lithium Ion SCHEMBL29368118 | 0.81 | GRIN3B (0.53) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL14409906 | 0.79 | GRIN3B (0.32) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL1460546 | 0.79 | KDR (0.46) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466027-B2 | Modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-10-11 | — | — | US | disclosed |
| US-20220213117-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| US-11358971-B2 | Prodrugs of modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-06-14 | — | — | US | disclosed |
| EP-3994141-A1 | MODULATORS OF THE NMDA RECEPTOR | H. Lundbeck A/S (DK) | 2022-05-11 | — | — | EP | disclosed |
| EP-3994140-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. Lundbeck A/S (DK) | 2022-05-11 | — | — | EP | disclosed |
| CN-114008053-A | Prodrugs of NMDA receptor modulators | H.隆德贝克有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114008054-A | NMDA receptor modulators | H.隆德贝克有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210047342-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-02-18 | — | — | US | disclosed |
| WO-2021001423-A1 | MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-01-07 | — | — | WO | disclosed |
| US-20210002292-A1 | MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-01-07 | — | — | US | disclosed |
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AUTRY CHRISTOPHER (US) | 2004-09-02 | — | — | US | disclosed |
| US-20040019065-A1 | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use | ROMINES WILLIAM HENRY (US) | 2004-01-29 | — | — | US | disclosed |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003106462-A1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003074529-A2 | iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-1287001-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2003000194-A2 | THIENOPYRIDINE AND THIENOPYRIMIDINE ANTICANCER AGENTS | PFIZER INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020042409-A1 | Thiophene derivatives useful as anticancer agents | PFIZER PRODUCTS INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | LUZZIO MICHAEL JOSEPH (US) | 2002-01-10 | — | — | US | disclosed |
| WO-2001094353-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | TK1, TYMP, DPYD | GRIN3B 4803/4885GRIN1 4237/4885GRIN2C 4785/4885 |
| US-11466027-B2 | Modulators of the NMDA receptor | GRIN1, GRIN2A, GRIN3A | GRIN3B 5/4885GRIN1 1/4885GRIN2C 8/4885 |
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | CCNA1, CCNE1, TP53 | GRIN3B 4853/4885GRIN1 4547/4885GRIN2C 4836/4885 |
| US-20040019065-A1 | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use | CDKN1A, CCNA1, TYMP | GRIN3B 4833/4885GRIN1 4417/4885GRIN2C 4864/4885 |
| US-11358971-B2 | Prodrugs of modulators of the NMDA receptor | GRIN3A, GRIN1, GRIN2A | GRIN3B 5/4885GRIN1 2/4885GRIN2C 6/4885 |
| US-20210002292-A1 | MODULATORS OF THE NMDA RECEPTOR | GRIN1, GRIN2A, GRIN3A | GRIN3B 5/4885GRIN1 1/4885GRIN2C 8/4885 |
| US-20210047342-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | GRIN3A, GRIN1, GRIN2A | GRIN3B 5/4885GRIN1 2/4885GRIN2C 6/4885 |
| US-20020042409-A1 | Thiophene derivatives useful as anticancer agents | TP53, RCC1, CCNA1 | GRIN3B 4823/4885GRIN1 4126/4885GRIN2C 4769/4885 |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | GRIN3B 4866/4885GRIN1 4541/4885GRIN2C 4754/4885 |
| US-20220213117-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | GRIN3A, GRIN1, GRIN2A | GRIN3B 5/4885GRIN1 2/4885GRIN2C 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.